Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P.

Science. 2000 Oct 27;290(5492):767-73.

2.

Biomedicine. Combating Parkinson's disease--step three.

Olson L.

Science. 2000 Oct 27;290(5492):721-4.

PMID:
11184202
3.

Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, Déglon N, Hantraye P, Aebischer P, Kordower JH.

J Neurosci. 2002 Jun 15;22(12):4942-54.

4.
5.

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.

Lo Bianco C, Déglon N, Pralong W, Aebischer P.

Neurobiol Dis. 2004 Nov;17(2):283-9.

PMID:
15474365
6.

Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.

Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC.

Exp Neurol. 2000 Nov;166(1):1-15.

PMID:
11031079
8.
9.
11.

Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.

Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P.

Exp Neurol. 2000 Jul;164(1):15-24.

PMID:
10877911
12.

Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.

Collier TJ, Dung Ling Z, Carvey PM, Fletcher-Turner A, Yurek DM, Sladek JR Jr, Kordower JH.

Exp Neurol. 2005 Feb;191 Suppl 1:S60-7.

PMID:
15629762
13.

Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.

Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.

Gene Ther. 1999 Dec;6(12):1936-51.

14.

Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.

Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K.

Gene Ther. 2002 Mar;9(6):381-9.

16.

GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice.

Date I, Aoi M, Tomita S, Collins F, Ohmoto T.

Neuroreport. 1998 Jul 13;9(10):2365-9.

PMID:
9694229
17.

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A.

Neuroreport. 2002 Jan 21;13(1):75-82.

PMID:
11924898
18.

Functional recovery in parkinsonian monkeys treated with GDNF.

Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA.

Nature. 1996 Mar 21;380(6571):252-5.

PMID:
8637574
19.

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.

Grondin R, Gash DM.

J Neurol. 1998 Nov;245(11 Suppl 3):P35-42. Review.

PMID:
9808338
20.

Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.

Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.

Exp Neurol. 2001 May;169(1):83-95.

PMID:
11312561
Items per page

Supplemental Content

Write to the Help Desk